Redx Pharma PLC
Small-molecule drugs for unmet needs
This article was originally published in Start Up
Executive Summary
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.
You may also be interested in...
BioHub At Alderley Park: A Bioincubator With A Difference
Once an R&D site for AstraZeneca, the BioHub at Alderley Park is now home to a number of emerging biotechs. Profiles of Absynth Biologics, Blueberry Therapeutics, Molplex, and OncoTherics.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways